Florian Krammer

The paper shows that two N1 neuraminidase monoclonal antibodies lose activity against recent H1N1 influenza viruses due to changes in electrostatic surface potential, but remain active against H5N1.

The paper shows that clonotype-restricted somatic hypermutations (SHMs) are associated with cryptic epitope recognition, while shared SHMs are permissive and not specific to particular epitopes.

An mRNA-based influenza vaccine induces broader and more durable B cell responses compared to inactivated influenza virus vaccine in humans.

This study uses gene-edited hematopoietic stem cells to create long-lived B lymphocyte protein factories that produce therapeutic antibodies against HIV-1, malaria, and influenza.

The paper assesses the breadth and vulnerability of vaccine-induced SARS-CoV-2 neutralizing antibodies against emerging variants by analyzing their binding to conserved and variant-associated epitopes.

This study identifies an immunodominant S2 apex epitope in SARS-CoV-2 that elicits a public antibody clonotype, highlighting its role as a barrier to universal coronavirus vaccines.

This paper evaluates a low-dose inactivated split virus vaccine against H5N1 influenza, showing cross-protective immunity against multiple clades in a mouse model.

The paper characterizes antigenic differences in H15 influenza virus hemagglutinin by analyzing mAb binding and neutralization against ancestral and drifted strains.

This study generates human monoclonal antibodies against H5N1 clade 2.3.4.4b HA, identifying four that neutralize the virus in vitro and show protective effects in mice.

This paper develops a method to discover monoclonal antibodies directly from immune sera using cryoEM and computational tools, significantly speeding up the process and improving accuracy.

This study shows that intranasal influenza vaccination generates durable local B cell memory in the upper airway, while intramuscular vaccination does not.

This study evaluates BECC adjuvants' ability to enhance HA-based influenza vaccine efficacy in mice, showing improved immune responses and viral clearance.

This study evaluates monoclonal antibody responses to XBB.1.5 vaccines by analyzing plasmablasts from vaccinated individuals and characterizing their binding and neutralization properties against SARS-CoV-2 variants.

This study evaluates two SARS-CoV-2 vaccines, AVX/COVID-12 (V-Wu) and V-BA, showing V-BA provides better protection against Omicron subvariants while V-Wu offers broader coverage against multiple variants.

The paper characterizes glycoproteins of novel fish influenza B-like viruses, revealing differences in receptor binding and antigenic conservation compared to influenza B viruses.

The paper identifies clonotype-enriched mutations in the light chain of a public antibody that enhance affinity for a conserved viral epitope and increase after repeated vaccinations.

This study evaluates an intranasal influenza vaccine based on neuraminidase (NA) adjuvanted with bacterial membrane-derived components, showing improved immunogenicity and protection against H5N1 challenge.

The paper identifies a multi-omics recovery factor predictive of long COVID using data from the IMPACC study, showing it can predict LC risk early after infection.

Immunaut identifies distinct immunophenotypic responder groups shaped by baseline immune landscapes using a comprehensive LAIV dataset, advancing precision vaccinology and guiding personalized immunization strategies.

The paper analyzes T cell epitopes from H5N1 and seasonal influenza viruses, finding conserved epitopes and cross-reactivity, suggesting pre-existing immunity may reduce H5N1 severity.

This study identifies immune subtypes in hospitalized COVID-19 patients linked to clinical outcomes and long COVID risk through longitudinal multi-omics analysis.

This study investigates viral reactivation in COVID-19 patients, finding associations between reactivation of specific virus families and clinical outcomes, including mortality and PASC symptoms.

This study identifies non-neutralizing antibodies from vaccinated individuals that protect against SARS-CoV-2 in animal models, highlighting their role through Fc-mediated effector functions and conserved epitope binding.

This study shows that pre-existing H1N1 immunity protects ferrets from severe disease caused by bovine H5N1 influenza virus.

This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.

The paper detects H5N1 clade 2.3.4.4b influenza viruses in urban birds in New York City and highlights the urban animal-human interface as a potential zoonotic risk.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.